[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642443":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":59,"collaborators":26,"id":62,"slug":26,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":96,"whyStopped":26,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Sana'a University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nifedipine 20 mg oral capsules","EXPERIMENTAL","Oral nifedipine 20 mg capsule twice daily (every 12 hours) for 14 consecutive days. First dose administered 6 hours after surgery.",[13],"Drug: Nifedipine 20 Mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo oral capsules","PLACEBO_COMPARATOR","Identical-appearing placebo capsule (same color, size, taste, and packaging) twice daily for 14 days, starting 6 hours after surgery.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Nifedipine 20 Mg","Nifedipine 20 mg immediate-release oral capsule, twice daily for 14 days. First dose 6 hours after surgery. L-type calcium channel blocker causing internal anal sphincter smooth-muscle relaxation, reduced resting pressure, improved local blood flow, and potential anti-inflammatory\u002Fanalgesic effects.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Inert placebo capsule matched to nifedipine in color, size, taste, and packaging. Administered twice daily for 14 days, starting 6 hours after surgery.",[15],[32],{"name":33,"affiliation":34,"role":35},"Dr. Yasser Abdurabo Obadiel, Associate Professor","Faculty of Medicine and Health Sciences, Sana'a University","STUDY_DIRECTOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Dr. Kholood Ahmed AL-Subari, M.B.B.Ch","CONTACT","+967772729669","drkholooda@gmail.com",[43],{"facility":44,"status":26,"city":45,"state":26,"zip":26,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Al-Jumhouri Teaching Hospital","Sanaa","Yemen",{"type":48,"coordinates":49},"Point",[50,51],44.20646,15.35452,{"lat":51,"lon":50},[54,55,57],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},{"name":33,"role":39,"phone":26,"phoneExt":26,"email":56},"Yasser.Obadiel@su.edu.ye",{"name":38,"role":58,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Haitham Mohammed Jowah","Lecturer","100642443",false,"NCT07659665","Oral Nifedipine Versus Placebo for Pain and Healing After Hemorrhoidectomy","The Effect of Oral Nifedipine Versus Placebo on Postoperative Pain and Healing Following Hemorrhoidectomy in Adult Patients: A Randomized Controlled Trial in Sana'a, Yemen","NIFEDIPINE-HD","Inclusion Criteria:\n\n* Adult patients aged 18-65 years\n* Scheduled for elective hemorrhoidectomy for grade III or IV hemorrhoids\n* Ability to provide written informed consent\n* Ability to understand and complete study questionnaires\n* Willingness to comply with the study protocol and follow-up visits\n\nExclusion Criteria:\n\n* Known hypersensitivity to nifedipine\n* Severe cardiovascular disease (unstable angina, recent myocardial infarction, severe heart failure)\n* Hypotension (systolic blood pressure \\\u003C 90 mmHg)\n* Severe hepatic or renal impairment\n* Pregnancy or breastfeeding\n* Current use of calcium channel blockers or nitrates\n* Emergency hemorrhoidectomy\n* Concurrent inflammatory bowel disease\n* History of anorectal surgery within the past 6 months","ALL","18 Years","65 Years",{"count":73,"type":74},100,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","The goal of this clinical trial is to evaluate whether oral nifedipine reduces postoperative pain and improves wound healing after hemorrhoidectomy in adult patients aged 18-65 years undergoing elective surgery for grade III or IV hemorrhoids in Sana'a, Yemen.\n\nThe main questions it aims to answer are:\n\n* Does oral nifedipine 20 mg twice daily for 14 days reduce postoperative pain compared with placebo?\n* Does oral nifedipine improve wound healing progression and shorten time to complete healing compared with placebo?\n\nResearchers will compare the nifedipine group to the placebo group to see if there is a significant reduction in pain scores, faster wound healing, lower analgesic consumption, and fewer complications.\n\nParticipants will:\n\n* Take either oral nifedipine 20 mg or an identical-looking placebo capsule twice daily for 14 consecutive days, starting 6 hours after surgery.\n* Report pain intensity using a standard 0-10 Visual Analogue Scale at multiple time points during the first 28 days.\n* Attend follow-up visits on postoperative days 7, 14, and 28 for wound healing assessment and safety monitoring.\n* Use rescue analgesia (paracetamol and\u002For diclofenac) as needed for breakthrough pain.",[80,81,82,83],"Hemorrhoids","Postoperative Pain","Wound Healing","Analgesia",[85,86,87,88,89,90,91,46,28,92,93,94,95],"Hemorrhoidectomy","Post-hemorrhoidectomy pain","Internal anal sphincter","Anal sphincter spasm","Nifedipine","Calcium channel blocker","Randomized controlled trial","Visual Analogue Scale","Pain management","Wound healing","Ecchymosis Discharge Approximation score","NOT_YET_RECRUITING","2026-06-27",{"date":99,"type":100},"2026-07-01","ACTUAL",{"date":102,"type":74},"2026-08-01",{"date":104,"type":74},"2026-12-30",{"name":5,"class":6},1]